Agressive Lymphoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04231747) | Juno Therapeutics, a Subsidiary of Celgene | 2020-05-21 |
Track Agressive Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.